Abbott Laboratories (ABT) Cash from Operations (2009 - 2026)

Abbott Laboratories has disclosed Cash from Operations across 18 years of filings, most recently posting $2.5 billion for Q2 2026.

• In Q2 2026, Cash from Operations rose 21.54% year-over-year to $2.5 billion; the TTM figure through Jun 2026 stood at $9.9 billion (up 9.6% YoY), while the FY2025 annual figure was $9.6 billion, up 11.78% from the prior year.
• Cash from Operations came in at $2.5 billion for Q2 2026 at Abbott Laboratories, up from $1.3 billion in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of $3.3 billion in Q4 2025 to a low of $1.0 billion in Q1 2024.
• Average Cash from Operations over 5 years is $2.2 billion, with a median of $2.2 billion recorded in 2022.
• Year-over-year, Cash from Operations tumbled 50.08% in 2023 and soared 62.93% in 2024.
• Over 5 years, Cash from Operations stood at $2.3 billion in 2022, then soared by 30.61% to $3.0 billion in 2023, then declined by 5.6% to $2.9 billion in 2024, then gained by 15.59% to $3.3 billion in 2025, then declined by 24.95% to $2.5 billion in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were $2.5 billion in Q2 2026, $1.3 billion in Q1 2026, and $3.3 billion in Q4 2025.